DBL Vinblastine

DBL Vinblastine

vinblastine

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma

Marketer:

DKSH
Concise Prescribing Info
Contents
Vinblastine sulfate
Indications/Uses
Hodgkin's disease (stages 3 & 4), advanced testicular carcinoma. Palliative treatment of lymphocytic & histiocytic lymphoma, advanced stages of mycosis fungoides, Kaposi's sarcoma, histiocytosis X. Choriocarcinoma resistant to other chemotherapeutic agents & breast carcinoma unresponsive to appropriate endocrine surgery & hormonal therapy.
Dosage/Direction for Use
Adult 1st dose: 3.7 mg/m2 once every 7 days. 2nd dose: 5.5 mg/m2 once every 7 days. 3rd dose: 7.4 mg/m2 once every 7 days. 4th dose: 9.25 mg/m2 once every 7 days. 5th dose: 11.1 mg/m2 once every 7 days. Increased dosage may be continued but must not exceed 18.5 mg/m2 once every 7 days. Childn 1st dose: 2.5 mg/m2 once every 7 days. 2nd dose: 3.75 mg/m2 once every 7 days. 3rd dose: 5 mg/m2 once every 7 days. 4th dose: 6.25 mg/m2 once every 7 days. 5th dose: 7.5 mg/m2 once every 7 days. Increased dosage may be continued but must not exceed 12.5 mg/m2 once every 7 days. Discontinue dosage increase for adult & childn after dose which reduces white cell count to approx 3 x 109/L (3,000/mm3).
Contraindications
Hypersensitivity. Leukopenia. Not be used in presence of bacterial infection.
Special Precautions
Not to be given IM, SC or intrathecally. Avoid inj into extremities. Malignant-cell bone marrow infiltration. Chicken pox (existing or recent exposure), herpes zoster, gout or urate renal stones history, infection. Monitor carefully for infection until white cell count has returned to normal levels if leukopenia w/ <2 x 109 WBC/L (2,000/mm3) occurs. Avoid long-term therapy & eye contamination. Not to be administered w/ live vaccines. Hepatic impairment. Not to be used during pregnancy. Not recommended during lactation. Avoid use in elderly w/ cachexia or ulcerated skin surface areas.
Adverse Reactions
Leukopenia, anaemia, thrombocytopenia; GI disorders; neurologic effects; malaise, weakness, dizziness, tumour site pain, skin vesiculation, HTN, bone & jaw pain, Raynaud’s phenomenon, inappropriate antidiuretic hormone secretion (high dose), hypersensitivity reactions; alopecia; extravasation.
Drug Interactions
Bone marrow suppressants eg, azathioprine, interferon, chloramphenicol, amphotericin B, colchicine, flucytosine & zidovudine. Reduced phenytoin blood levels & increased seizure activity. Potentially life-threatening infection w/ live vaccine immunisation. Serious life-threatening CV toxicity w/ bleomycin & cisplatin. Increased lung disease w/ mitomycin.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01CA01 - vinblastine ; Belongs to the class of plant alkaloids and other natural products, vinca alkaloids and analogues. Used in the treatment of cancer.
Presentation/Packing
Form
DBL Vinblastine inj 10 mg/10 mL
Packing/Price
5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in